Full-Time
Biotechnology company for aesthetic solutions
$102.5k - $140.9k/yr
Mid, Senior
Newark, CA, USA
Get referrals →
You have ways to get a Revance referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Revance Therapeutics, Inc. specializes in aesthetic and therapeutic solutions, primarily focusing on products that enhance physical appearance and improve patient outcomes. The company offers neuromodulators, like botulinum toxin type A, which reduce wrinkles and treat muscle movement disorders, and dermal fillers that restore volume and smooth facial lines. Revance is also exploring therapeutic uses for its products in treating muscle movement and pain disorders. Additionally, the company has expanded into the fintech sector with the acquisition of HintMD, a platform that streamlines payment processes for aesthetic practices. This integration allows Revance to provide a comprehensive suite of services to support aesthetic practitioners. Unlike its competitors, Revance emphasizes differentiated products and improved patient experiences, aiming to establish itself as a leader in the premium aesthetics market.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Nashville, Tennessee
Founded
1999
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Unlimited Paid Time Off
401(k) Company Match
Professional Development Budget
Evolus has strategically targeted a younger audience with its wrinkle treatment Jeuveau, setting itself apart from competitors like Revance and AbbVie, which usually focus on clients in their 40s.
In addition, under the Distribution Agreement, Revance is required to meet certain minimum purchase obligations and certain minimum expenditure requirements and either party may terminate the Distribution Agreement in the event of "a material breach by the other party."
Crown offer of $3.65 per share is the only offer available to Revance stockholders. Crown offer unanimously approved by the Revance Board of Directors. Teoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender
Revance Therapeutics is set to go private with Crown Laboratories by Feb. 6. Crown has increased its offer to $3.65 per share, a 17% rise from the previous $3.10 offer. The deal, endorsed by Revance's board, is the only fully-financed offer available. The initial $6.66 offer was paused due to a breach with Teoxane, but a settlement has been reached. Revance's shares were trading at $3.63, with a 52-week range of $2.30-$7.56. The offer is valid until Feb. 4.
From Washington, DC but with Oak Ridge ties: Teresa Robbins has been named as the Acting Administrator of the National Nuclear Security Administration (NNSA). Prior to this, she served as... The post News Notes | Acting Administrator of National Nuclear Security Administration has Oak Ridge ties appeared first on Teknovation.biz.